Repligen Corp
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Waltham, MA
RGEN chart
What traders are saying about $RGEN
Latest postsRepligen Corp news
- Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts Guidance
Yahoo Finance ·
- Repligen Posts Record Q3 Revenue, Narrows 2026 Organic Growth Outlook
TradingKey ·
- Repligen (RGEN) Stock Faces Q3 Earnings Margin Squeeze
Simply Wall Street ·
- Record Revenue Outlook Could Be A Game Changer For Repligen (RGEN)
Yahoo Finance ·
- Repligen (RGEN) Takes $41.2 Million Impairment Charge As Quarterly Profit Turns To Loss
Yahoo Finance ·
- Repligen Corp (RGEN) Q3 2026 Earnings Call Highlights: Record Re
GuruFocus ·
- Repligen (RGEN) Stock Looks Reasonably Priced As Cash Flow Expectations Settle
Simply Wall Street ·
- Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Is Priced In
Yahoo Finance ·
- Repligen slips as investors weigh filtration weakness against strong Q3 results
Quiver Quantitative ·
- Repligen Corporation Q3 2026 Earnings Call Summary
app.moby.co ·
- Repligen Corporation Reports Intangible Asset Impairment Charges for the Third Quarter Ended September 30, 2026
marketscreener.com ·
- Repligen (RGEN) Q3 2026 Earnings Call Transcript
fool.com ·
Repligen Corp key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | $48.9M | -$25.5M | $35.6M | $186.0M |
| Diluted EPS | $0.86 | $-0.46 | $0.63 | $3.24 |
| Total assets (year end) | $2.95B | $2.83B | $2.83B | $2.53B |
| Cash and equivalents (year end) | $566.0M | $757.4M | $751.3M | $523.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Repligen Corp
- Ticker
- RGEN (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 730272
Frequently asked questions
What exchange is Repligen Corp listed on?
Repligen Corp trades on the Nasdaq under the ticker symbol RGEN.
What industry is Repligen Corp in?
Repligen Corp is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Repligen Corp headquartered?
Repligen Corp's business address on file with the SEC is in Waltham, MA.
When does Repligen Corp's fiscal year end?
Repligen Corp's fiscal year ends on December 31.
How much revenue did Repligen Corp report?
Repligen Corp reported $141.2M in revenue for calendar year 2017, according to its SEC filings.